Skip to main content

Advertisement

SpringerLink
Log in

Advances in the Current Treatment of Autoimmune Hepatitis

  • Review
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Current treatment strategies for autoimmune hepatitis are complicated by frequent relapse after drug withdrawal, medication intolerance, and refractory disease. The objective of this review is to describe advances that have improved treatment outcomes by defining the optimum objectives of initial therapy, managing relapse more effectively, identifying problematic patients early, and incorporating the new pharmacological interventions that have emerged as frontline and salvage therapies. Initial corticosteroid treatment should be continued until serum aminotransferase, γ-globulin, and immunoglobulin G levels are normal, and maintenance of this improvement for 3–8 months before liver tissue assessment. Improvement to normal liver tissue is the ideal histological result that justifies drug withdrawal, but it is achievable in only 22 % of patients. Minimum portal hepatitis, inactive cirrhosis, or minimally active cirrhosis is the most common treatment end point. Relapse after drug withdrawal warrants institution of a long-term maintenance regimen, preferably with azathioprine. Mathematical models can identify problematic adult patients early, as also can clinical phenotype (age ≤30 years and HLA DRB1*03), rapidity of treatment response (≤24 months), presence of antibodies to soluble liver antigen, and non-white ethnicity. The calcineurin inhibitors (cyclosporine and tacrolimus) can be effective in steroid-refractory disease; mycophenolate mofetil can be corticosteroid-sparing and effective for azathioprine intolerance; budesonide combined with azathioprine can be effective for treatment-naïve, non-cirrhotic patients. Standard treatment regimens for autoimmune hepatitis can be upgraded without adjustments that require major new expertise.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med. 1971;40:159–185.

    PubMed  CAS  Google Scholar 

  2. Soloway RD, Summerskill WH, Baggenstoss AH, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology. 1972;63:820–833.

    PubMed  CAS  Google Scholar 

  3. Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet. 1973;1:735–737.

    Article  PubMed  CAS  Google Scholar 

  4. Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol. 2004;40:646–652.

    Article  PubMed  CAS  Google Scholar 

  5. Mohamadnejad M, Malekzadeh R, Nasseri-Moghaddam S, et al. Impact of immunosuppressive treatment on liver fibrosis in autoimmune hepatitis. Dig Dis Sci. 2005;50:547–551.

    Article  PubMed  CAS  Google Scholar 

  6. Roberts SK, Therneau TM, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology. 1996;110:848–857.

    Article  PubMed  CAS  Google Scholar 

  7. Floreani A, Niro G. Rosa Rizzotto E, et al. Type I autoimmune hepatitis: clinical course and outcome in an Italian multicentre study. Aliment Pharmacol Ther. 2006;24:1051–1057.

    Article  PubMed  CAS  Google Scholar 

  8. Seo S, Toutounjian R, Conrad A, Blatt L, Tong MJ. Favorable outcomes of autoimmune hepatitis in a community clinic setting. J Gastroenterol Hepatol. 2008;23:1410–1414.

    Article  PubMed  Google Scholar 

  9. Manns MP, Czaja AJ, Gorham JD, et al. Practice guidelines of the American association for the study of liver diseases. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51:2193–2213.

    Article  PubMed  CAS  Google Scholar 

  10. Czaja AJ, Bianchi FB, Carpenter HA, et al. Treatment challenges and investigational opportunities in autoimmune hepatitis. Hepatology. 2005;41:207–215.

    Article  PubMed  Google Scholar 

  11. Montano-Loza AJ, Carpenter HA, Czaja AJ. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. Hepatology. 2007;46:1138–1145.

    Article  PubMed  CAS  Google Scholar 

  12. Czaja AJ, Davis GL, Ludwig J, Taswell HF. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology. 1984;4:622–627.

    Article  PubMed  CAS  Google Scholar 

  13. Czaja AJ. Safety issues in the management of autoimmune hepatitis. Expert Opin Drug Saf. 2008;7:319–333.

    Article  PubMed  CAS  Google Scholar 

  14. Czaja AJ, Ammon HV, Summerskill WH. Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission. Gastroenterology. 1980;78:518–523.

    PubMed  CAS  Google Scholar 

  15. Hegarty JE, Nouri Aria KT, Portmann B, Eddleston AL, Williams R. Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatology. 1983;3:685–689.

    Article  PubMed  CAS  Google Scholar 

  16. Czaja AJ, Menon KV, Carpenter HA. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology. 2002;35:890–897.

    Article  PubMed  CAS  Google Scholar 

  17. Czaja AJ. Current and future treatments of autoimmune hepatitis. Expert Rev Gastroenterol Hepatol. 2009;3:269–291.

    Article  PubMed  CAS  Google Scholar 

  18. Czaja AJ. Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis. Dig Dis Sci. 2010;55:2712–2726.

    Article  PubMed  Google Scholar 

  19. Czaja AJ. Promising pharmacological, molecular and cellular treatments of autoimmune hepatitis. Curr Pharm Design. 2011;17:3120–3140.

    Article  CAS  Google Scholar 

  20. Alvarez F, Berg PA, Bianchi FB, et al. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929–938.

    Article  PubMed  CAS  Google Scholar 

  21. Czaja AJ, Manns MP. Advances in the diagnosis, pathogenesis and management of autoimmune hepatitis. Gastroenterology. 2010;139:58–72.

    Article  PubMed  CAS  Google Scholar 

  22. Hyams JS, Ballow M, Leichtner AM. Cyclosporine treatment of autoimmune chronic active hepatitis. Gastroenterology. 1987;93:890–893.

    PubMed  CAS  Google Scholar 

  23. Person JL, McHutchison JG, Fong TL, Redeker AG. A case of cyclosporine-sensitive, steroid-resistant, autoimmune chronic active hepatitis. J Clin Gastroenterol. 1993;17:317–320.

    Article  PubMed  CAS  Google Scholar 

  24. Van Thiel DH, Wright H, Carroll P, et al. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am J Gastroenterol. 1995;90:771–776.

    PubMed  Google Scholar 

  25. Jackson LD, Song E. Cyclosporin in the treatment of corticosteroid resistant autoimmune chronic active hepatitis. Gut. 1995;36:459–461.

    Article  PubMed  CAS  Google Scholar 

  26. Debray D, Maggiore G, Girardet JP, Mallet E, Bernard O. Efficacy of cyclosporin A in children with type 2 autoimmune hepatitis. J Pediatr. 1999;135:111–114.

    Article  PubMed  CAS  Google Scholar 

  27. Fernandes NF, Redeker AG, Vierling JM, Villamil FG, Fong TL. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am J Gastroenterol. 1999;94:241–248.

    Article  PubMed  CAS  Google Scholar 

  28. Malekzadeh R, Nasseri-Moghaddam S, Kaviani MJ, et al. Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig Dis Sci. 2001;46:1321–1327.

    Article  PubMed  CAS  Google Scholar 

  29. Hurtova M, Duclos-Vallee JC, Johanet C, et al. Successful tacrolimus therapy for a severe recurrence of type 1 autoimmune hepatitis in a liver graft recipient. Liver Transpl. 2001;7:556–558.

    Article  PubMed  CAS  Google Scholar 

  30. Aqel BA, Machicao V, Rosser B, et al. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J Clin Gastroenterol. 2004;38:805–809.

    Article  PubMed  CAS  Google Scholar 

  31. Larsen FS, Vainer B, Eefsen M, Bjerring PN, Adel Hansen B. Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis. World J Gastroenterol. 2007;13:3232–3236.

    PubMed  CAS  Google Scholar 

  32. Tannous MM, Cheng J, Muniyappa K, et al. Use of tacrolimus in the treatment of autoimmune hepatitis: a single centre experience. Aliment Pharmacol Ther. 2011;34:405–407.

    Article  PubMed  CAS  Google Scholar 

  33. Danielsson A, Prytz H. Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther. 1994;8:585–590.

    Article  PubMed  CAS  Google Scholar 

  34. Wiegand J, Schuler A, Kanzler S, et al. Budesonide in previously untreated autoimmune hepatitis. Liver Int. 2005;25:927–934.

    Article  PubMed  CAS  Google Scholar 

  35. Csepregi A, Rocken C, Treiber G, Malfertheiner P. Budesonide induces complete remission in autoimmune hepatitis. World J Gastroenterol. 2006;12:1362–1366.

    PubMed  CAS  Google Scholar 

  36. Zandieh I, Krygier D, Wong V, et al. The use of budesonide in the treatment of autoimmune hepatitis in Canada. Can J Gastroenterol. 2008;22:388–392.

    PubMed  Google Scholar 

  37. Manns MP, Woynarowski M, Kreisel W, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology. 2010;139:1198–1206.

    Article  PubMed  CAS  Google Scholar 

  38. Snider KR, Potter TG. Budesonide for the treatment of autoimmune hepatitis. Ann Pharmacother. 2011;45:1144–1150.

    Article  PubMed  CAS  Google Scholar 

  39. Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol. 2000;33:371–375.

    Article  PubMed  CAS  Google Scholar 

  40. Devlin SM, Swain MG, Urbanski SJ, Burak KW. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. Can J Gastroenterol. 2004;18:321–326.

    PubMed  Google Scholar 

  41. Czaja AJ, Carpenter HA. Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease. J Clin Gastroenterol. 2005;39:819–825.

    Article  PubMed  CAS  Google Scholar 

  42. Inductivo-Yu I, Adams A, Gish RG, et al. Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy. Clin Gastroenterol Hepatol. 2007;5:799–802.

    Article  PubMed  CAS  Google Scholar 

  43. Hennes EM, Oo YH, Schramm C, et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am J Gastroenterol. 2008;103:3063–3070.

    Article  PubMed  CAS  Google Scholar 

  44. Hlivko JT, Shiffman ML, Stravitz RT, et al. A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis. Clin Gastroenterol Hepatol. 2008;6:1036–1040.

    Article  PubMed  CAS  Google Scholar 

  45. Aw MM, Dhawan A, Samyn M, Bargiota A, Mieli-Vergani G. Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up. J Hepatol. 2009;51:156–160.

    Article  PubMed  CAS  Google Scholar 

  46. Wolf DC, Bojito L, Facciuto M, Lebovics E. Mycophenolate mofetil for autoimmune hepatitis: a single practice experience. Dig Dis Sci. 2009;54:2519–2522.

    Article  PubMed  CAS  Google Scholar 

  47. Sharzehi K, Huang MA, Schreibman IR, Brown KA. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy. Can J Gastroenterol. 2010;24:588–592.

    PubMed  Google Scholar 

  48. Zachou K, Gatselis N, Papadamou G, Rigopoulou EI, Dalekos GN. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naive patients. J Hepatol. 2011;55:636–646.

    Article  PubMed  CAS  Google Scholar 

  49. Baven-Pronk AM, Coenraad MJ, van Buuren HR, et al. The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes. Aliment Pharmacol Ther. 2011;34:335–343.

    Article  PubMed  CAS  Google Scholar 

  50. Fallatah HI, Akbar HO. Mycophenolate mofetil as a rescue therapy for autoimmune hepatitis patients who are not responsive to standard therapy. Expert Rev Gastroenterol Hepatol. 2011;5:517–522.

    Article  PubMed  CAS  Google Scholar 

  51. Czaja AJ, Beaver SJ, Shiels MT. Sustained remission after corticosteroid therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. Gastroenterology. 1987;92:215–219.

    PubMed  CAS  Google Scholar 

  52. Montano-Loza AJ, Carpenter HA, Czaja AJ. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol. 2007;102:1005–1012.

    Article  PubMed  CAS  Google Scholar 

  53. Kanzler S, Lohr H, Gerken G, Galle PR, Lohse AW. Long-term management and prognosis of autoimmune hepatitis (AIH): a single center experience. Z Gastroenterol. 2001;39:339–341, 344–338.

    Google Scholar 

  54. Kanzler S, Gerken G, Lohr H, et al. Duration of immunosuppressive therapy in autoimmune hepatitis. J Hepatol. 2001;34:354–355.

    Article  PubMed  CAS  Google Scholar 

  55. Czaja AJ, Wolf AM, Baggenstoss AH. Laboratory assessment of severe chronic active liver disease during and after corticosteroid therapy: correlation of serum transaminase and gamma globulin levels with histologic features. Gastroenterology. 1981;80:687–692.

    PubMed  CAS  Google Scholar 

  56. Luth S, Herkel J, Kanzler S, et al. Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis. J Clin Gastroenterol. 2008;42:926–930.

    Article  PubMed  CAS  Google Scholar 

  57. Czaja AJ, Ludwig J, Baggenstoss AH, Wolf A. Corticosteroid-treated chronic active hepatitis in remission: uncertain prognosis of chronic persistent hepatitis. N Engl J Med. 1981;304:5–9.

    Article  PubMed  CAS  Google Scholar 

  58. Czaja AJ. Late relapse of type 1 autoimmune hepatitis after corticosteroid withdrawal. Dig Dis Sci. 2010;55:1761–1769.

    Article  PubMed  CAS  Google Scholar 

  59. Verma S, Gunuwan B, Mendler M, Govindrajan S, Redeker A. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am J Gastroenterol. 2004;99:1510–1516.

    Article  PubMed  Google Scholar 

  60. Davis GL, Czaja AJ, Ludwig J. Development and prognosis of histologic cirrhosis in corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis. Gastroenterology. 1984;87:1222–1227.

    PubMed  CAS  Google Scholar 

  61. Schalm SW, Korman MG, Summerskill WH, Czaja AJ, Baggenstoss AH. Severe chronic active liver disease. Prognostic significance of initial morphologic patterns. Am J Dig Dis. 1977;22:973–980.

    Article  PubMed  CAS  Google Scholar 

  62. Baggenstoss AH, Soloway RD, Summerskill WH, Elveback LR, Schoenfield LJ. Chronic active liver disease. The range of histologic lesions, their response to treatment, and evolution. Hum Pathol. 1972;3:183–198.

    Article  PubMed  CAS  Google Scholar 

  63. Czaja AJ, Carpenter HA. Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. Liver Int. 2003;23:116–123.

    Article  PubMed  Google Scholar 

  64. Soloway RD, Baggenstoss AH, Schoenfield LJ, Summerskill WH. Observer error and sampling variability tested in evaluation of hepatitis and cirrhosis by liver biopsy. Am J Dig Dis. 1971;16:1082–1086.

    Article  PubMed  CAS  Google Scholar 

  65. Theodossi A, Skene AM, Portmann B, et al. Observer variation in assessment of liver biopsies including analysis by kappa statistics. Gastroenterology. 1980;79:232–241.

    PubMed  CAS  Google Scholar 

  66. Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. Hepatology. 2002;36:479–497.

    Article  PubMed  Google Scholar 

  67. Muratori L, Muratori P, Lanzoni G, Ferri S, Lenzi M. Application of the 2010 American Association for the study of liver diseases criteria of remission to a cohort of Italian patients with autoimmune hepatitis. Hepatology. 2010;52:1857; author reply 1857–1858.

    Google Scholar 

  68. Miyake Y, Iwasaki Y, Terada R, et al. Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis. J Hepatol. 2005;43:951–957.

    Article  PubMed  CAS  Google Scholar 

  69. Vergani D, Choudhuri K, Bogdanos DP, Mieli-Vergani G. Pathogenesis of autoimmune hepatitis. Clin Liver Dis. 2002;6:727–737.

    Article  PubMed  Google Scholar 

  70. Czaja AJ. Autoimmune hepatitis. Part A: Pathogenesis. Expert Rev Gastroenterol Hepatol. 2007;1:113–128.

    Article  PubMed  CAS  Google Scholar 

  71. Montano-Loza AJ, Carpenter HA, Czaja AJ. Consequences of treatment withdrawal in type 1 autoimmune hepatitis. Liver Int. 2007;27:507–515.

    Article  PubMed  CAS  Google Scholar 

  72. Stellon AJ, Keating JJ, Johnson PJ, McFarlane IG, Williams R. Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal. Hepatology. 1988;8:781–784.

    Article  PubMed  CAS  Google Scholar 

  73. Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med. 1995;333:958–963.

    Article  PubMed  CAS  Google Scholar 

  74. Czaja AJ. Low-dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis. Hepatology. 1990;11:1044–1049.

    Article  PubMed  CAS  Google Scholar 

  75. Seela S, Sheela H, Boyer JL. Autoimmune hepatitis type 1: safety and efficacy of prolonged medical therapy. Liver Int. 2005;25:734–739.

    Article  PubMed  CAS  Google Scholar 

  76. Schalm SW, Ammon HV, Summerskill WH. Failure of customary treatment in chronic active liver disease: causes and management. Ann Clin Res. 1976;8:221–227.

    PubMed  CAS  Google Scholar 

  77. Czaja AJ, Davis GL, Ludwig J, Baggenstoss AH, Taswell HF. Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology. Gastroenterology. 1983;85:713–717.

    PubMed  CAS  Google Scholar 

  78. Yeoman AD, Westbrook RH, Zen Y, et al. Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis. Hepatology. 2011;53:926–934.

    Article  PubMed  Google Scholar 

  79. Sanchez-Urdazpal L, Czaja AJ, van Hoek B, Krom RA, Wiesner RH. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatology. 1992;15:215–221.

    Article  PubMed  CAS  Google Scholar 

  80. Czaja AJ, Rakela J, Ludwig J. Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology. 1988;95:448–453.

    PubMed  CAS  Google Scholar 

  81. Czaja AJ. Autoantibodies as prognostic markers in autoimmune liver disease. Dig Dis Sci. 2010;55:2144–2161.

    Article  PubMed  CAS  Google Scholar 

  82. Czaja AJ. Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. J Hepatol. 2009;51:161–167.

    Article  PubMed  CAS  Google Scholar 

  83. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology. 1993;105:1502–1507.

    Article  PubMed  CAS  Google Scholar 

  84. Czaja AJ, Strettell MD, Thomson LJ, et al. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology. 1997;25:317–323.

    Article  PubMed  CAS  Google Scholar 

  85. Czaja AJ, Carpenter HA. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology. 2006;43:532–538.

    Article  PubMed  Google Scholar 

  86. De Paoli P, Battistin S, Santini GF. Age-related changes in human lymphocyte subsets: progressive reduction of the CD4 CD45R (suppressor inducer) population. Clin Immunol Immunopathol. 1988;48:290–296.

    Article  PubMed  Google Scholar 

  87. Murasko DM, Goonewardene IM. T-cell function in aging: mechanisms of decline. Annu Rev Gerontol Geriatr. 1990;10:71–96.

    PubMed  CAS  Google Scholar 

  88. Talor E, Rose NR. Hypothesis: the aging paradox and autoimmune disease. Autoimmunity. 1991;8:245–249.

    Article  PubMed  CAS  Google Scholar 

  89. Schwab R, Russo C, Weksler ME. Altered major histocompatibility complex-restricted antigen recognition by T cells from elderly humans. Eur J Immunol. 1992;22:2989–2993.

    Article  PubMed  CAS  Google Scholar 

  90. Rowley MJ, Buchanan H, Mackay IR. Reciprocal change with age in antibody to extrinsic and intrinsic antigens. Lancet. 1968;2:24–26.

    Article  PubMed  CAS  Google Scholar 

  91. Czaja AJ. Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis. Clin Gastroenterol Hepatol. 2008;6:379–388.

    Article  PubMed  CAS  Google Scholar 

  92. Manns M, Gerken G, Kyriatsoulis A, Staritz M. Meyer zum Buschenfelde KH. Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet. 1987;1:292–294.

    Article  PubMed  CAS  Google Scholar 

  93. Stechemesser E, Klein R, Berg PA. Characterization and clinical relevance of liver-pancreas antibodies in autoimmune hepatitis. Hepatology. 1993;18:1–9.

    Article  PubMed  CAS  Google Scholar 

  94. Wies I, Brunner S, Henninger J, et al. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet. 2000;355:1510–1515.

    Article  PubMed  CAS  Google Scholar 

  95. Volkmann M, Luithle D, Zentgraf H, et al. SLA/LP/tRNP((Ser)Sec) antigen in autoimmune hepatitis: identification of the native protein in human hepatic cell extract. J Autoimmun. 2010;34:59–65.

    Article  PubMed  CAS  Google Scholar 

  96. Volkmann M, Martin L, Baurle A, et al. Soluble liver antigen: isolation of a 35-kd recombinant protein (SLA-p35) specifically recognizing sera from patients with autoimmune hepatitis. Hepatology. 2001;33:591–596.

    Article  PubMed  CAS  Google Scholar 

  97. Costa M, Rodriguez-Sanchez JL, Czaja AJ, Gelpi C. Isolation and characterization of cDNA encoding the antigenic protein of the human tRNP(Ser)Sec complex recognized by autoantibodies from patients withtype-1 autoimmune hepatitis. Clin Exp Immunol. 2000;121:364–374.

    Article  PubMed  CAS  Google Scholar 

  98. Gelpi C, Sontheimer EJ, Rodriguez-Sanchez JL. Autoantibodies against a serine tRNA-protein complex implicated in cotranslational selenocysteine insertion. Proc Natl Acad Sci USA. 1992;89:9739–9743.

    Article  PubMed  CAS  Google Scholar 

  99. Baeres M, Herkel J, Czaja AJ, et al. Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut. 2002;51:259–264.

    Article  PubMed  CAS  Google Scholar 

  100. Czaja AJ, Shums Z, Norman GL. Frequency and significance of antibodies to soluble liver antigen/liver pancreas in variant autoimmune hepatitis. Autoimmunity. 2002;35:475–483.

    Article  PubMed  CAS  Google Scholar 

  101. Ma Y, Okamoto M, Thomas MG, et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology. 2002;35:658–664.

    Article  PubMed  CAS  Google Scholar 

  102. Czaja AJ, Donaldson PT, Lohse AW. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis. Am J Gastroenterol. 2002;97:413–419.

    Article  PubMed  Google Scholar 

  103. Liaskos C, Bogdanos DP, Rigopoulou EI, et al. Antibody responses specific for soluble liver antigen co-occur with Ro-52 autoantibodies in patients with autoimmune hepatitis (abstract). J Hepatol. 2007;46:S250.

    Article  Google Scholar 

  104. Eyraud V, Chazouilleres O, Ballot E, et al. Significance of antibodies to soluble liver antigen/liver pancreas: a large French study. Liver Int. 2009;29:857–864.

    Article  PubMed  CAS  Google Scholar 

  105. Montano-Loza AJ, Shums Z, Norman GL, Czaja AJ. Prognostic implications of antibodies to Ro/SSA and soluble liver antigen in type 1 autoimmune hepatitis. Liver Int. 2012;32:85–92.

    Article  PubMed  CAS  Google Scholar 

  106. Mix H, Weiler-Normann C, Thimme R, et al. Identification of CD4 T-cell epitopes in soluble liver antigen/liver pancreas autoantigen in autoimmune hepatitis. Gastroenterology. 2008;135:2107–2118.

    Article  PubMed  CAS  Google Scholar 

  107. Czaja AJ. Diverse manifestations and evolving treatments of autoimmune hepatitis. Minerva Gastroenterol Dietol. 2005;51:313–333.

    PubMed  CAS  Google Scholar 

  108. Czaja AJ. Special clinical challenges in autoimmune hepatitis: the elderly, males, pregnancy, mild disease, fulminant onset, and nonwhite patients. Semin Liver Dis. 2009;29:315–330.

    Article  PubMed  Google Scholar 

  109. Czaja AJ, Bayraktar Y. Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment. World J Gastroenterol. 2009;15:2314–2328.

    Article  PubMed  CAS  Google Scholar 

  110. Czaja AJ. Autoimmune hepatitis in special patient populations. Best Pract Res Clin Gastroenterol. 2011;25:689–700.

    Article  PubMed  Google Scholar 

  111. Lim KN, Casanova RL, Boyer TD, Bruno CJ. Autoimmune hepatitis in African Americans: presenting features and response to therapy. Am J Gastroenterol. 2001;96:3390–3394.

    Article  PubMed  CAS  Google Scholar 

  112. Verma S, Torbenson M, Thuluvath PJ. The impact of ethnicity on the natural history of autoimmune hepatitis. Hepatology. 2007;46:1828–1835.

    Article  PubMed  Google Scholar 

  113. Hurlburt KJ, McMahon BJ, Deubner H, et al. Prevalence of autoimmune liver disease in Alaska Natives. Am J Gastroenterol. 2002;97:2402–2407.

    Article  PubMed  Google Scholar 

  114. Minuk GY, Liu S, Kaita K, et al. Autoimmune hepatitis in a North American Aboriginal/First Nations population. Can J Gastroenterol. 2008;22:829–834.

    PubMed  CAS  Google Scholar 

  115. Zolfino T, Heneghan MA, Norris S, et al. Characteristics of autoimmune hepatitis in patients who are not of European Caucasoid ethnic origin. Gut. 2002;50:713–717.

    Article  PubMed  CAS  Google Scholar 

  116. Nakamura K, Yoneda M, Yokohama S, et al. Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol. 1998;13:490–495.

    Article  PubMed  CAS  Google Scholar 

  117. Miyakawa H, Kawashima Y, Kitazawa E, et al. Low frequency of anti-SLA/LP autoantibody in Japanese adult patients with autoimmune liver diseases: analysis with recombinant antigen assay. J Autoimmun. 2003;21:77–82.

    Article  PubMed  CAS  Google Scholar 

  118. Bittencourt PL, Goldberg AC, Cancado EL, et al. Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2. Am J Gastroenterol. 1999;94:1906–1913.

    Article  PubMed  CAS  Google Scholar 

  119. Czaja AJ, Souto EO, Bittencourt PL, et al. Clinical distinctions and pathogenic implications of type 1 autoimmune hepatitis in Brazil and the United States. J Hepatol. 2002;37:302–308.

    Article  PubMed  Google Scholar 

  120. Fainboim L, Marcos Y, Pando M, et al. Chronic active autoimmune hepatitis in children. Strong association with a particular HLA-DR6 (DRB1*1301) haplotype. Hum Immunol. 1994;41:146–150.

    Article  PubMed  CAS  Google Scholar 

  121. Pando M, Larriba J, Fernandez GC, et al. Pediatric and adult forms of type I autoimmune hepatitis in Argentina: evidence for differential genetic predisposition. Hepatology. 1999;30:1374–1380.

    Article  PubMed  CAS  Google Scholar 

  122. D’Souza R, Sinnott P, Glynn MJ, Sabin CA, Foster GR. An unusual form of autoimmune hepatitis in young Somalian men. Liver Int. 2005;25:325–330.

    Article  PubMed  Google Scholar 

  123. Nguyen GC, Segev DL, Thuluvath PJ. Racial disparities in the management of hospitalized patients with cirrhosis and complications of portal hypertension: a national study. Hepatology. 2007;45:1282–1289.

    Article  PubMed  Google Scholar 

  124. Nguyen GC, Thuluvath PJ. Racial disparity in liver disease: biological, cultural, or socioeconomic factors. Hepatology. 2008;47:1058–1066.

    Article  PubMed  Google Scholar 

  125. Flores YN, Yee HF Jr, Leng M, et al. Risk factors for chronic liver disease in Blacks, Mexican Americans, and Whites in the United States: results from NHANES IV, 1999–2004. Am J Gastroenterol. 2008;103:2231–2238.

    Article  PubMed  Google Scholar 

  126. Vento S, Garofano T, Di Perri G, et al. Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals. Lancet. 1991;337:1183–1187.

    Article  PubMed  CAS  Google Scholar 

  127. Huppertz HI, Treichel U, Gassel AM, Jeschke R. Meyer zum Buschenfelde KH. Autoimmune hepatitis following hepatitis A virus infection. J Hepatol. 1995;23:204–208.

    Article  PubMed  CAS  Google Scholar 

  128. Fainboim L, Canero Velasco MC, Marcos CY, et al. Protracted, but not acute, hepatitis A virus infection is strongly associated with HLA-DRB*1301, a marker for pediatric autoimmune hepatitis. Hepatology. 2001;33:1512–1517.

    Google Scholar 

  129. Muratori P, Czaja AJ, Muratori L, et al. Genetic distinctions between autoimmune hepatitis in Italy and North America. World J Gastroenterol. 2005;11:1862–1866.

    PubMed  Google Scholar 

  130. Muratori P, Czaja AJ, Muratori L, et al. Evidence of a genetic basis for the different geographic occurrences of liver/kidney microsomal antibody type 1 in hepatitis C. Dig Dis Sci. 2007;52:179–184.

    Article  PubMed  Google Scholar 

  131. Manns MP. Autoimmune hepatitis: the dilemma of rare diseases. Gastroenterology. 2011;140:1874–1876.

    Article  PubMed  Google Scholar 

  132. Manns MP, Strassburg CP. Therapeutic strategies for autoimmune hepatitis. Dig Dis. 2011;29:411–415.

    Article  PubMed  Google Scholar 

  133. Turner JD, Thomas AP, Reeves JP, Hantash BM. Calcineurin activation by slow calcium release from intracellular stores suppresses protein kinase C regulation of L-type calcium channels in L6 cells. Cell Calcium. 2009;46:242–247.

    Article  PubMed  CAS  Google Scholar 

  134. Martinez–Martinez S, Redondo JM. Inhibitors of the calcineurin/NFAT pathway. Curr Med Chem. 2004;11:997–1007.

    Article  PubMed  Google Scholar 

  135. Serfling E, Berberich-Siebelt F, Avots A, et al. NFAT and NF-kappaB factors-the distant relatives. Int J Biochem Cell Biol. 2004;36:1166–1170.

    Article  PubMed  CAS  Google Scholar 

  136. Macian F. NFAT proteins: key regulators of T-cell development and function. Nat Rev Immunol. 2005;5:472–484.

    Article  PubMed  CAS  Google Scholar 

  137. de Jonge H, Naesens M, Kuypers DR. New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation. Ther Drug Monit. 2009;31:416–435.

    Article  PubMed  CAS  Google Scholar 

  138. Canafax DM, Ascher NL. Cyclosporine immunosuppression. Clin Pharm. 1983;2:515–524.

    PubMed  CAS  Google Scholar 

  139. Allison AC. Immunosuppressive drugs: the first 50 years and a glance forward. Immunopharmacology. 2000;47:63–83.

    Article  PubMed  CAS  Google Scholar 

  140. Almawi WY, Assi JW, Chudzik DM, Jaoude MM, Rieder MJ. Inhibition of cytokine production and cytokine-stimulated T-cell activation by FK506 (tacrolimus)1. Cell Transplant. 2001;10:615–623.

    PubMed  CAS  Google Scholar 

  141. Iwasaki K. Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug Metab Pharmacokinet. 2007;22:328–335.

    Article  PubMed  CAS  Google Scholar 

  142. Liu J, Farmer JD Jr, Lane WS, et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell. 1991;66:807–815.

    Article  PubMed  CAS  Google Scholar 

  143. Galat A, Bua J. Molecular aspects of cyclophilins mediating therapeutic actions of their ligands. Cell Mol Life Sci. 2010;67:3467–3488.

    Article  PubMed  CAS  Google Scholar 

  144. Siekierka JJ, Hung SH, Poe M, Lin CS, Sigal NH. A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature. 1989;341:755–757.

    Article  PubMed  CAS  Google Scholar 

  145. Wang T, Donahoe PK, Zervos AS. Specific interaction of type I receptors of the TGF-beta family with the immunophilin FKBP-12. Science. 1994;265:674–676.

    Article  PubMed  CAS  Google Scholar 

  146. Jorgensen KA, Koefoed-Nielsen PB, Karamperis N. Calcineurin phosphatase activity and immunosuppression. A review on the role of calcineurin phosphatase activity and the immunosuppressive effect of cyclosporin A and tacrolimus. Scand J Immunol. 2003;57:93–98.

    Article  PubMed  CAS  Google Scholar 

  147. Pissaia A, Jr, Aoudjehane L, Ben Othman S, et al. Cyclosporine inhibits profibrotic effects of interleukin-4 and transforming growth factor beta on human intrahepatic fibroblasts cultured in vitro. Transplant Proc. 2010;42:4343–4346.

    Google Scholar 

  148. Mistilis SP, Vickers CR, Darroch MH, McCarthy SW. Cyclosporin, a new treatment for autoimmune chronic active hepatitis. Med J Aust. 1985;143:463–465.

    PubMed  CAS  Google Scholar 

  149. Sherman KE, Narkewicz M, Pinto PC. Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis. J Hepatol. 1994;21:1040–1047.

    Article  PubMed  CAS  Google Scholar 

  150. Alvarez F, Ciocca M, Canero-Velasco C, et al. Short-term cyclosporine induces a remission of autoimmune hepatitis in children. J Hepatol. 1999;30:222–227.

    Article  PubMed  CAS  Google Scholar 

  151. Cuarterolo M, Ciocca M, Velasco CC, et al. Follow-up of children with autoimmune hepatitis treated with cyclosporine. J Pediatr Gastroenterol Nutr. 2006;43:635–639.

    Article  PubMed  CAS  Google Scholar 

  152. Cuarterolo ML, Ciocca ME, Lopez SI, de Davila MT, Alvarez F. Immunosuppressive therapy allows recovery from liver failure in children with autoimmune hepatitis. Clin Gastroenterol Hepatol. 2011;9:145–149.

    Article  PubMed  CAS  Google Scholar 

  153. Chatur N, Ramji A, Bain VG, et al. Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int. 2005;25:723–727.

    Article  PubMed  CAS  Google Scholar 

  154. Winkler M, Christians U. A risk-benefit assessment of tacrolimus in transplantation. Drug Saf. 1995;12:348–357.

    Article  PubMed  CAS  Google Scholar 

  155. Lohse AW, Weiler-Norman C, Burdelski M. De novo autoimmune hepatitis after liver transplantation. Hepatol Res. 2007;37:S462.

    Article  PubMed  Google Scholar 

  156. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47:85–118.

    Article  PubMed  CAS  Google Scholar 

  157. Allison AC. Mechanisms of action of mycophenolate mofetil. Lupus. 2005;14:s2–s8.

    Article  PubMed  CAS  Google Scholar 

  158. Morath C, Schwenger V, Beimler J, et al. Antifibrotic actions of mycophenolic acid. Clin Transpl. 2006;20:25–29.

    Article  Google Scholar 

  159. Czaja AJ. Mycophenolate mofetil to the rescue in autoimmune hepatitis: a fresh sprout on the decision tree. J Hepatol. 2009;51:8–10.

    Article  PubMed  CAS  Google Scholar 

  160. Adams B, Lazarchick J, Medina AM, et al. Iatrogenic immunodeficiency-associated lymphoproliferative disease of the Hodgkin lymphoma-like variant in a patient treated with mycophenolate mofetil for autoimmune hepatitis. Am J Hematol. 2010;85:627–629.

    Article  PubMed  CAS  Google Scholar 

  161. Perez-Aytes A, Ledo A, Boso V, et al. In utero exposure to mycophenolate mofetil: a characteristic phenotype? Am J Med Genet A. 2008;146A:1–7.

    Article  PubMed  Google Scholar 

  162. Anderka MT, Lin AE, Abuelo DN, Mitchell AA, Rasmussen SA. Reviewing the evidence for mycophenolate mofetil as a new teratogen: case report and review of the literature. Am J Med Genet A. 2009;149A:1241–1248.

    Article  PubMed  Google Scholar 

  163. Klieger-Grossmann C, Chitayat D, Lavign S, et al. Prenatal exposure to mycophenolate mofetil: an updated estimate. J Obstet Gynaecol Can. 2010;32:794–797.

    PubMed  Google Scholar 

  164. Lin AE, Singh KE, Strauss A, et al. An additional patient with mycophenolate mofetil embryopathy: cardiac and facial analyses. Am J Med Genet A. 2011;155A:748–756.

    PubMed  Google Scholar 

  165. Seikaly MG. Mycophenolate mofetil—is it worth the cost? The in-favor opinion. Pediatr Transplant. 1999;3:79–82.

    Article  PubMed  CAS  Google Scholar 

  166. Heneghan MA, Al-Chalabi T, McFarlane IG. Cost-effectiveness of pharmacotherapy for autoimmune hepatitis. Expert Opin Pharmacother. 2006;7:145–156.

    Article  PubMed  Google Scholar 

  167. Clissold SP, Heel RC. Budesonide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in asthma and rhinitis. Drugs. 1984;28:485–518.

    Article  PubMed  CAS  Google Scholar 

  168. Czaja AJ, Lindor KD. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology. 2000;119:1312–1316.

    Article  PubMed  CAS  Google Scholar 

  169. Geier A, Gartung C, Dietrich CG, et al. Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC. World J Gastroenterol. 2003;9:2681–2685.

    PubMed  Google Scholar 

  170. Efe C, Ozaslan E, Kav T, et al. Liver fibrosis may reduce the efficacy of budesonide in the treatment of autoimmune hepatitis and overlap syndrome. Autoimmun Rev. Epub. 10/06/2011.

  171. Lohse AW, Gil H. Reactivation of autoimmune hepatitis during budesonide monotherapy, and response to standard treatment. J Hepatol. 2011;54:837–839.

    Article  PubMed  Google Scholar 

  172. Czaja AJ. Features and consequences of untreated type 1 autoimmune hepatitis. Liver Int. 2009;29:816–823.

    Article  PubMed  CAS  Google Scholar 

  173. Feld JJ, Dinh H, Arenovich T, et al. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology. 2005;42:53–62.

    Article  PubMed  Google Scholar 

  174. Czaja AJ. Difficult treatment decisions in autoimmune hepatitis. World J Gastroenterol. 2010;16:934–947.

    Article  PubMed  CAS  Google Scholar 

  175. de Boer NK, van Nieuwkerk CM, Aparicio Pages MN, et al. Promising treatment of autoimmune hepatitis with 6-thioguanine after adverse events on azathioprine. Eur J Gastroenterol Hepatol. 2005;17:457–461.

    Google Scholar 

  176. Nikolaeva N, Bemelman FJ, Yong SL, van Lier RA, ten Berge IJ. Rapamycin does not induce anergy but inhibits expansion and differentiation of alloreactive human T cells. Transplantation. 2006;81:445–454.

    Article  PubMed  CAS  Google Scholar 

  177. Ronis MJ, Butura A, Sampey BP, et al. Effects of N-acetylcysteine on ethanol-induced hepatotoxicity in rats fed via total enteral nutrition. Free Radic Biol Med. 2005;39:619–630.

    Article  PubMed  CAS  Google Scholar 

  178. Bemeur C, Vaquero J, Desjardins P, Butterworth RF. N-acetylcysteine attenuates cerebral complications of non-acetaminophen-induced acute liver failure in mice: antioxidant and anti-inflammatory mechanisms. Metab Brain Dis. 2010;25:241–249.

    Article  PubMed  CAS  Google Scholar 

  179. Baumgardner JN, Shankar K, Hennings L, et al. N-acetylcysteine attenuates progression of liver pathology in a rat model of nonalcoholic steatohepatitis. J Nutr. 2008;138:1872–1879.

    PubMed  CAS  Google Scholar 

  180. Setshedi M, Longato L, Petersen DR, et al. Limited therapeutic effect of N-acetylcysteine on hepatic insulin resistance in an experimental model of alcohol-induced steatohepatitis. Alcohol Clin Exp Res. Epub. 07/28/2011.

  181. Desai D, Kaushal N, Gandhi UH, et al. Synthesis and evaluation of the anti-inflammatory properties of selenium-derivatives of celecoxib. Chem Biol Interact. 2010;188:446–456.

    Article  PubMed  CAS  Google Scholar 

  182. Smith CA, Williams GT, Kingston R, Jenkinson EJ, Owen JJ. Antibodies to CD3/T-cell receptor complex induce death by apoptosis in immature T cells in thymic cultures. Nature. 1989;337:181–184.

    Article  PubMed  CAS  Google Scholar 

  183. von Herrath MG, Coon B, Wolfe T, Chatenoud L. Nonmitogenic CD3 antibody reverses virally induced (rat insulin promoter-lymphocytic choriomeningitis virus) autoimmune diabetes without impeding viral clearance. J Immunol. 2002;168:933–941.

    Google Scholar 

  184. Chatenoud L. Anti-CD3 antibodies: towards clinical antigen-specific immunomodulation. Curr Opin Pharmacol. 2004;4:403–407.

    Article  PubMed  CAS  Google Scholar 

  185. Chatenoud L, Thervet E, Primo J, Bach JF. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci USA. 1994;91:123–127.

    Article  PubMed  CAS  Google Scholar 

  186. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med. 2002;346:1692–1698.

    Article  PubMed  CAS  Google Scholar 

  187. Herold KC, Gitelman SE, Masharani U, et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala–Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes. 2005;54:1763–1769.

    Article  PubMed  CAS  Google Scholar 

  188. Schwartz JC, Zhang X, Fedorov AA, Nathenson SG, Almo SC. Structural basis for co-stimulation by the human CTLA-4/B7-2 complex. Nature. 2001;410:604–608.

    Article  PubMed  CAS  Google Scholar 

  189. Scalapino KJ, Daikh DI. CTLA-4: a key regulatory point in the control of autoimmune disease. Immunol Rev. 2008;223:143–155.

    Article  PubMed  CAS  Google Scholar 

  190. Weyand CM, Goronzy JJ. T-cell-targeted therapies in rheumatoid arthritis. Nat Clin Pract Rheumatol. 2006;2:201–210.

    Article  PubMed  CAS  Google Scholar 

  191. Maxwell L, Singh JA. Abatacept for rheumatoid arthritis. Cochrane Database Syst Rev. 2009:CD007277.

  192. Chen W, Perruche S, Li J. CD4+ CD25+ T regulatory cells and TGF-beta in mucosal immune system: the good and the bad. Curr Med Chem. 2007;14:2245–2249.

    Article  PubMed  CAS  Google Scholar 

  193. Longhi MS, Ma Y, Bogdanos DP, et al. Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. J Hepatol. 2004;41:31–37.

    Article  PubMed  CAS  Google Scholar 

  194. Longhi MS, Hussain MJ, Mitry RR, et al. Functional study of CD4+ CD25+ regulatory T cells in health and autoimmune hepatitis. J Immunol. 2006;176:4484–4491.

    PubMed  CAS  Google Scholar 

  195. Longhi MS, Meda F, Wang P, et al. Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis. Hepatology. 2008;47:581–591.

    Article  PubMed  CAS  Google Scholar 

  196. Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol. 1997;84:223–243.

    Article  PubMed  CAS  Google Scholar 

  197. Kim WR, Brown RS Jr, Terrault NA, El-Serag H. Burden of liver disease in the United States: summary of a workshop. Hepatology. 2002;36:227–242.

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

Albert J. Czaja, MD has no conflict of interests to declare.

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First Street S.W., Rochester, MN, 55905, USA

    Albert J. Czaja

Authors
  1. Albert J. Czaja
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Albert J. Czaja.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Czaja, A.J. Advances in the Current Treatment of Autoimmune Hepatitis. Dig Dis Sci 57, 1996–2010 (2012). https://doi.org/10.1007/s10620-012-2151-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-012-2151-2

Keywords

Search

Navigation